Fed Rate Hike Odds Rise as Hot Inflation Report Reshapes Market Expectations Ferrari Aims to Prove Skeptics Wrong Following Polarizing Electric Vehicle Launch China Trade Official Steps In as Commerce Minister Skips APEC Meeting Over Urgent Official Business Venezuela Taps Socialist Banker Matthieu Pigasse to Navigate Financial Crisis and Lure Investors US Fuel Prices May Not Normalize This Year Even If Iran Conflict Ends Analysis Suggests Options Trading Without BlackScholes Model Chart Reading Gains Prominence Deckers Outdoor DECK Q1 2026 Earnings EPS Surges Past Estimates Stock Jumps 4 ONCY Q3 2025 Earnings WiderthanExpected Loss Amid Clinical Progress ACTU Q1 2026 Earnings EPS Miss Weighs on Shares as Biotech Firm Navigates EarlyStage Pipeline LUMN Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Restructuring Challenges Persist Titan Mining Corporation TII Q1 2026 Earnings Profitability Surprise Drives Positive EPS Yet Stock Slides SSYS Q1 2026 Earnings Narrower Loss Surprises Market Shares Rally LandBridge LB Shares Slip 264 as Resistance Holds Near 7557 KE Holdings BEKE Edges Higher as Stock Holds Near Support DarkIris Inc DKI Hovers Near Support as Selling Pressure Eases Atea Pharmaceuticals AVIR Edges Higher Amid Renewed Investor Interest Ares Commercial Real Estate ACRE Slides 2 as Commercial Real Estate Headwinds Persist Chinese Investors Flock to Dividend Stocks Amid Limited Alternatives TriplePoint Venture Growth BDC Corp TPVG Q1 2026 Earnings EPS Misses Estimates Amid Venture Debt Market Pressures BlackRock Science and Technology Term Trust BSTZ Rises 113 as Tech Sentiment Improves Inflation Reacceleration Broadens Beyond Oil Rising Costs in Rent Food and Services Diodes Inc CEO Gary Yu Sells 399810 in Stock Insider Transaction Highlights Jobless Claims Remain Subdued Signaling Continued Labor Market Tightness SpaceX IPO Speculation Drives Surge in SpaceTheme Stocks and ETFs Portugals Meo Sues State for 82 Million Over Huawei 5G Equipment Ban 99 of CEOs Expect AIDriven Layoffs Within Two Years Mercer Study Shows Regeneron and Parabilis Medicines Forge 232 Billion Deal to Target Undruggable Proteins